Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade

Different biomarkers based on genomics variants have been used to predict the response of patients treated with PD-1/programmed death receptor 1 ligand (PD-L1) blockade. We aimed to use deep-learning algorithm to estimate clinical benefit in patients with non-small-cell lung cancer (NSCLC) before im...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jie, Zhang, Jing, Zou, Dan, Xiao, Lushan, Ma, Honglian, Zhang, Xudong, Li, Ya, Han, Lijie, Xie, Baowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677530/
https://www.ncbi.nlm.nih.gov/pubmed/36420269
http://dx.doi.org/10.3389/fimmu.2022.960459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677530/
https://www.ncbi.nlm.nih.gov/pubmed/36420269
http://dx.doi.org/10.3389/fimmu.2022.960459

Ejemplares similares